Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
US-San Francisco CA-UCSF, San Francisco, California, United States
Contact: Study coordinator (R. Olin)US-Atlanta GA-EMORY, Atlanta, Georgia, United States
Contact: Study coordinator (W. Blum)US-Kansas City KS-KUMC, Kansas City, Kansas, United States
Contact: Study coordinator (T. Lin)US-Baltimore MD-UMGCCC, Baltimore, Maryland, United States
Contact: Study coordinator (M. Baer)US-St Louis MO-WASHU, St Louis, Missouri, United States
Contact: Study coordinator (G. Uy)US-Cincinnati OH-CINCY, Cincinnati, Ohio, United States
Contact: Study coordinator (E. Curran)AU-Adelaide-FLINDERS, Adelaide, Australia
Contact: Study coordinator (A. Beligaswatte)AU-Adelaide-RAH, Adelaide, Australia
Contact: Study coordinator (D. Hiwase)AU-Birtinya-SUNSHINECOAST, Birtinya, Australia
Contact: Study coordinator (J. Conn)AU-Brisbane-PAH, Brisbane, Australia
Contact: Study coordinator (M. Harwood)AU-Camperdown-RPA, Camperdown, Australia
Contact: Study coordinator (D. Mc Culloch)AU-Melbourne-AUSTIN, Melbourne, Australia
Contact: Study coordinator (C.Y. Fong)AU-Melbourne-PMCC, Melbourne, Australia
Contact: Study coordinator (A. Wei)AU-Sydney-WSAH, Sydney, Australia
Contact: Study coordinator (L. Vaughan)BE-Antwerpen-ZAS, Antwerp, Belgium
Contact: Study coordinator (D. Breems)Be-Charleroi-GHDC, Charleroi, Belgium
Contact: Study coordinator (V. Robin)BE-Geel-STDIMPNA, Geel, Belgium
Contact: Study coordinator (U. Douven)BE-Gent-UZGENT, Ghent, Belgium
Contact: Study coordinator (T. De Corte)BE-Haine-Saint-Paul-JOLIMONT, Jolimont, Belgium
Contact: Study coordinator (R. Lattenist)BE-Liege-CHULIEGE, Liège, Belgium
Contact: Study coordinator (A. De Voeght)BE-Liege-MONTLEGIA, Liège, Belgium
Contact: Study coordinator (Q. Perlot)BE-Yvoir-MONTGODINNE, Yvoir, Belgium
Contact: Study coordinator (E. Collinge)FI-Oulu-OYS, Oulu, Finland
Contact: Study coordinator (K. Launonen)DE-Bochum-RUB, Bochum, Germany
Contact: Study coordinator (R. Schroers)DE-Greifswald-UNIGREIFSWALD, Greifswald, Germany
Contact: Study coordinator (J. Krönke)DE-Passau-KLINIKUMPASSAU, Passau, Germany
Contact: Study coordinator (T. Suedhoff)DE-Ulm-UNIKLINKULM, Ulm, Germany
Contact: Study coordinator (H. Döhner)JP-Nagasaki Shi-NAGASAKI, Nagasaki, Japan
Contact: Study coordinator (K. Ando)NL-Amersfoort-MEANDERMC, Amersfoort, Netherlands
Contact: Study coordinator (M.F. Corsten)NL-Amsterdam-AMSTERDAMUMC, Amsterdam, Netherlands
Contact: Study coordinator (D.C. de Leeuw)NL-Amsterdam-OLVG, Amsterdam, Netherlands
Contact: Study coordinator (H. Mooij)NL-Arnhem-RIJNSTATE, Arnhem, Netherlands
Contact: Study coordinator (M. Cuipers)NL-Breda-AMPHIA, Breda, Netherlands
Contact: Study coordinator (R. Fiets)NL-Dordrecht-ASZ, Dordrecht, Netherlands
Contact: Study coordinator (P. Westerweel)NL-Eindhoven-MAXIMAMC, Eindhoven, Netherlands
Contact: Study coordinator (L. Tick)NL-Groningen-UMCG, Groningen, Netherlands
Contact: Study coordinator (G. Huls)NL-Leeuwarden-FRISIUSMC, Leeuwarden, Netherlands
Contact: Study coordinator (B. Franken)NL-Leiden-LUMC, Leiden, Netherlands
Contact: Study coordinator (J.H. Veelken)NL-Nieuwegein-ANTONIUS, Nieuwegein, Netherlands
Contact: Study coordinator (M. Söhne)NL-Nijmegen-RADBOUD, Nijmegen, Netherlands
Contact: Study coordinator (F. in 't Hout)NL-Rotterdam-ERASMUCMC, Rotterdam, Netherlands
Contact: Study coordinator (M.H.G. Raaijmakers)NL-Den Haag-HAGA, The Hague, Netherlands
Contact: Study coordinator (D. Lammeren, van-Venema)SE-Lund-Suh, Lund, Sweden
Contact: Study coordinator (V. Lazarevic)
Study leads
M.H.G.P. Raaijmakers
Principal Investigator
Erasmus Medical Center